$RSII READ CLOSELY, MARIJUANA Pharmaceutical stock
Post# of 266
"I feel that Rising BioSciences will deliver shareholder value in a big way," states DiPrima. "There are ample prospects within the MMJ R&D markets, particularly those budding in the pharmaceutical compounding sector. Rising BioSciences seeks to fulfill a yet-to-be-met market demand with a first to market approach so that patients across the U.S. get the treatment they so desperately need without falling subject to the dangers of opiates, whose long-term effects can include liver damage, dependence/addiction and brain damage due to hypoxia, resulting from respiratory depression, among other complications."
patients ACROSS the U.S.
This is going to be unreal with Management Ties!!